Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 25, 2017 ) Publisher's "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the CMV for theglobal, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMVfrom 2013-2023. According to Publisher, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023. Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.
For more information about this report: http://www.reportsweb.com/cytomegalovirus-cmv-infection-market-insights-epidemiology-and-market-forecast-2023-global
As per Publisher's estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013-2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs. - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023. - It also provides Market size of Cytomegalovirus (CMV) infection for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Table Of Content:- Cytomegalovirus Infections Disease Overview Symptoms of cytomegalovirus (CMV) Infection Etiology Risk Factors Pathogenesis of human cytomegalovirus Pathophysiology of cytomegalovirus infection Diagnosis Treatment Algorithm for Cytomegalovirus Infections Treatment for Congenital CMV Infection Treatment of Ganciclovir resistant CMV Treatment Guidelines Recommendations for Treating Cytomegalovirus Infections Disease Management Epidemiology and Patient Population Global Global CMV Prevalent, Diagnosed and Treatable Cases United States Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV Europe Italy
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001426092/sample
Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV Spain Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV United Kingdom Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV Germany Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV France Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infants Patients at High Risk of CMV HIV Patients at High Risk of CMV Japan Assumptions and Rationale Total CMV Prevalent, Diagnosed and Treatable Cases CMV Patients among Transplants Infant Patients at High Risk of CMV HIV Patients at High Risk of CMV in Japan Unmet Medical Needs Marketed Products Valcyte (Valganciclovir hydrochloride) Advantages & Disadvantages Product Profile Efficacy Safety Side effects of Drug SWOT Analysis FOSCAVIR (foscarnet sodium) Advantages & Disadvantages Product Profile Efficacy Safety Side effects of Drug SWOT Analysis CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human) Advantages & Disadvantages Product Profile Efficacy Safety Side effects of Drug SWOT Analysis CytoTect CP Advantages & Disadvantages Product Profile Efficacy Safety Side effects of Drug SWOT Analysis Valtrex (Valacyclovir hydrochloride) Advantages & Disadvantages Product Profile Efficacy Safety Side effects of Drug SWOT Analysis Emerging Products Analysis Emerging Therapies 1. Approved Products Cytovir CMV: Cell Medica Ltd. Product Description Research and Development Product Development Activities 2. Pipeline Products (Phase III) CytoTect CP 70: Biotest AG. Product Description Advantages & Disadvantages Research and Development Product Development Activities Letermovir: Merck & Co. Product Description Advantages & Disadvantages Research and Development Product Development Activities Brincidofovir: Chimerix Inc. Product Description Advantages & Disadvantages Research and Development Product Development Activities ASP0113: Astellas Pharma Global Development, Inc. Product Description Advantages & Disadvantages Research and Development Product Development Activities Human Cytomegalovirus Immune Globulin: CSL Behring Product Description Advantages & Disadvantages Research and Development Product Development Activities Global Market Size United States Europe Italy Germany France Spain United Kingdom Japan Market Drivers Market Barriers Appendix Report Methodology Consulting Services Disclaimer
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001426092/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|